_id
690db58fccc777a4e85d0dc9
Ticker
BCAB
Name
Bioatla Inc
Exchange
NASDAQ
Address
11085 Torreyana Road, San Diego, CA, United States, 92121
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.bioatla.com
Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Last Close
0.7832
Volume
587593
Current Price
0.8244
Change
5.260469867211442
Last Updated
2025-11-28T12:44:36.806Z
Image
data:image/webp;base64,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
Ipo Date
2020-12-16T00:00:00.000Z
Market Cap
50014432
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9872500000000001
Sentiment Sources
4
Rating
4.25
Target Price
10
Strong Buy
2
Buy
1
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
56000
Gross Profit
-56000
Operating Expenses
13733000
Operating Income
-13789000
Interest Expense
-
Pretax Income
-15778000
Net Income
-15778000
Eps
-0.2685829921871424
Dividends Per Share
-
Shares Outstanding
58792088
Income Tax Expense
-
EBITDA
-15722000
Operating Margin
-
Total Other Income Expense Net
-1989000
Cash
8320000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
9670000
Property Plant Equipment
6075000
Total Assets
15908000
Payables
5851000
Short Term Debt
1173000
Long Term Debt
-
Total Liabilities
47145000
Equity
-31237000
Depreciation
56000
Change In Working Capital
1414000
Cash From Operations
-9881000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-6000
Net Change In Cash
-9887000
PE
-
PB
-1.5503941085635624
ROE
50.510612414764545
ROA
-99.18280110636158
FCF
-9881000
Fcf Percent
-
Piotroski FScore
1
Health Score
39
Deep Value Investing Score
1.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
2.5
Net Net Investing Score
0.5
Quality Investing Score
3
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
56000
Quarters > 0 > income Statement > gross Profit
-56000
Quarters > 0 > income Statement > operating Expenses
13733000
Quarters > 0 > income Statement > operating Income
-13789000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-15778000
Quarters > 0 > income Statement > net Income
-15778000
Quarters > 0 > income Statement > eps
-0.2685829921871424
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
58745343
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-15722000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-1989000
Quarters > 0 > balance Sheet > cash
8320000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
9670000
Quarters > 0 > balance Sheet > property Plant Equipment
6075000
Quarters > 0 > balance Sheet > total Assets
15908000
Quarters > 0 > balance Sheet > payables
5851000
Quarters > 0 > balance Sheet > short Term Debt
1173000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
47145000
Quarters > 0 > balance Sheet > equity
-31237000
Quarters > 0 > cash Flow > net Income
-15778000
Quarters > 0 > cash Flow > depreciation
56000
Quarters > 0 > cash Flow > change In Working Capital
1414000
Quarters > 0 > cash Flow > cash From Operations
-9881000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-6000
Quarters > 0 > cash Flow > net Change In Cash
-9887000
Quarters > 0 > ratios > PE
-0.2685829921871424
Quarters > 0 > ratios > PB
-1.5503941085635624
Quarters > 0 > ratios > ROE
50.510612414764545
Quarters > 0 > ratios > ROA
-99.18280110636158
Quarters > 0 > ratios > FCF
-9881000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
39
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
567000
Quarters > 1 > income Statement > gross Profit
-567000
Quarters > 1 > income Statement > operating Expenses
18080000
Quarters > 1 > income Statement > operating Income
-18647000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-18711000
Quarters > 1 > income Statement > net Income
-18711000
Quarters > 1 > income Statement > eps
-0.31982212071721927
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
58504396
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-18532000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-64000
Quarters > 1 > balance Sheet > cash
18207000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
20613000
Quarters > 1 > balance Sheet > property Plant Equipment
6353000
Quarters > 1 > balance Sheet > total Assets
27129000
Quarters > 1 > balance Sheet > payables
4643000
Quarters > 1 > balance Sheet > short Term Debt
805000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
43874000
Quarters > 1 > balance Sheet > equity
-16745000
Quarters > 1 > cash Flow > net Income
-18711000
Quarters > 1 > cash Flow > depreciation
115000
Quarters > 1 > cash Flow > change In Working Capital
2802000
Quarters > 1 > cash Flow > cash From Operations
-14198000
Quarters > 1 > cash Flow > capital Expenditures
14198000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
42000
Quarters > 1 > cash Flow > net Change In Cash
-14156000
Quarters > 1 > ratios > PE
-0.31982212071721927
Quarters > 1 > ratios > PB
-2.8803239213138254
Quarters > 1 > ratios > ROE
111.74081815467302
Quarters > 1 > ratios > ROA
-68.97047440008846
Quarters > 1 > ratios > FCF
-28396000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
183000
Quarters > 2 > income Statement > gross Profit
-183000
Quarters > 2 > income Statement > operating Expenses
17431000
Quarters > 2 > income Statement > operating Income
-17614000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-15334000
Quarters > 2 > income Statement > net Income
-15334000
Quarters > 2 > income Statement > eps
-0.2632481331168246
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
58249226
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-17431000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2280000
Quarters > 2 > balance Sheet > cash
32363000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
37537000
Quarters > 2 > balance Sheet > property Plant Equipment
753000
Quarters > 2 > balance Sheet > total Assets
38290000
Quarters > 2 > balance Sheet > payables
4698000
Quarters > 2 > balance Sheet > short Term Debt
554000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
37743000
Quarters > 2 > balance Sheet > equity
547000
Quarters > 2 > cash Flow > net Income
-15334000
Quarters > 2 > cash Flow > depreciation
183000
Quarters > 2 > cash Flow > change In Working Capital
-902000
Quarters > 2 > cash Flow > cash From Operations
-16288000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-395000
Quarters > 2 > cash Flow > net Change In Cash
-16683000
Quarters > 2 > ratios > PE
-0.2632481331168246
Quarters > 2 > ratios > PB
87.78914426764169
Quarters > 2 > ratios > ROE
-2803.2906764168188
Quarters > 2 > ratios > ROA
-40.04700966309741
Quarters > 2 > ratios > FCF
-16288000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
16
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
11650000
Quarters > 3 > income Statement > gross Profit
-11650000
Quarters > 3 > income Statement > operating Expenses
4594000
Quarters > 3 > income Statement > operating Income
-16244000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-14884000
Quarters > 3 > income Statement > net Income
-14884000
Quarters > 3 > income Statement > eps
-0.29798068635098307
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
49949546
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-16015999
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
1360000
Quarters > 3 > balance Sheet > cash
49046000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
51232000
Quarters > 3 > balance Sheet > property Plant Equipment
1190000
Quarters > 3 > balance Sheet > total Assets
52422000
Quarters > 3 > balance Sheet > payables
1902000
Quarters > 3 > balance Sheet > short Term Debt
836000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
38157000
Quarters > 3 > balance Sheet > equity
14265000
Quarters > 3 > cash Flow > net Income
-14884000
Quarters > 3 > cash Flow > depreciation
228000
Quarters > 3 > cash Flow > change In Working Capital
-3251000
Quarters > 3 > cash Flow > cash From Operations
-16783000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
9313000
Quarters > 3 > cash Flow > net Change In Cash
-7470000
Quarters > 3 > ratios > PE
-0.29798068635098307
Quarters > 3 > ratios > PB
2.8866740779810725
Quarters > 3 > ratios > ROE
-104.33929197336138
Quarters > 3 > ratios > ROA
-28.392659570409368
Quarters > 3 > ratios > FCF
-16783000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
28
Valuation > metrics > PE
-0.2685829921871424
Valuation > metrics > PB
-1.5503941085635624
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
50.510612414764545
Profitability > metrics > ROA
-163.16442605997932
Profitability > final Score
55
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-246.23214285714286
Risk > final Score
-955
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.3767084282460136
Liquidity > metrics > Quick Ratio
1.3767084282460136
Liquidity > final Score
84
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
20
Prev Valuations > 2
80
Prev Profitabilities > 0
55
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-387
Prev Risks > 1
-28
Prev Risks > 2
-39
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:16:00.100Z
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAcorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
12/13/2025
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB Defense World
Read more →Fibonacci Support Holding Strong in Aurionpro Solutions Limited - Equity Performance Review & Free Risk Assessment and Control earlytimes.in
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$10
Analyst Picks
Strong Buy
2
Buy
1
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 11.29% of the total shares of Bioatla Inc
1.
Vanguard Group Inc(3.0366%)
since
2025/06/30
2.
TANG CAPITAL MANAGEMENT LLC(2.34%)
since
2025/06/30
3.
Renaissance Technologies Corp(1.2844%)
since
2025/06/30
4.
Deutsche Bank AG(0.8947%)
since
2025/06/30
5.
Geode Capital Management, LLC(0.8383%)
since
2025/06/30
6.
BlackRock Inc(0.819%)
since
2025/06/30
7.
Morgan Stanley - Brokerage Accounts(0.5374%)
since
2025/06/30
8.
ADAR1 Capital Management LLC(0.2904%)
since
2025/06/30
9.
State Street Corp(0.2578%)
since
2025/06/30
10.
Northern Trust Corp(0.1717%)
since
2025/06/30
11.
Two Sigma Investments LLC(0.1407%)
since
2025/06/30
12.
Marshall Wace Asset Management Ltd(0.1377%)
since
2025/06/30
13.
Susquehanna International Group, LLP(0.1274%)
since
2025/06/30
14.
Magnus Financial Group LLC(0.0804%)
since
2025/06/30
15.
Mccormack Advisors International(0.0754%)
since
2025/06/30
16.
Alpha Cubed Investments LLC(0.0701%)
since
2025/06/30
17.
National Asset Management Inc(0.0511%)
since
2025/06/30
18.
UBS Group AG(0.0504%)
since
2025/06/30
19.
COLUMBIA ADVISORY PARTNERS LLC(0.0444%)
since
2025/06/30
20.
Commonwealth Equity Services Inc(0.0431%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.